title: Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.
abstract: Invariant natural killer T cells (iNKT) and dendritic cells (DC) play a central role in tumor immunity through downstream activation of immune effector cells by pro-inflammatory cytokines. Evidence is accumulating that the CD1d-iNKT cell axis can be effectively used to potentiate DC-based cancer vaccines. Here, we provide a detailed methodology for the generation of (CD1d-expressing) monocyte-derived DC (moDC) and their subsequent loading with the iNKT cell agonist α-galactosylceramide (α-GalCer) or their direct ligation by agonistic anti-CD1d monoclonal antibodies.
authors.affiliation: Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands.
authors.forename: Roeland
authors.initials: R
authors.lastname: Lameris
authors.forename: Famke L
authors.initials: FL
authors.lastname: Schneiders
authors.forename: Tanja D
authors.initials: TD
authors.lastname: de Gruijl
authors.forename: Hans J
authors.initials: HJ
authors.lastname: van der Vliet
mesh_terms: D000911:Antibodies, Monoclonal / Q000276:immunology; D055610:Antigens, CD1d / Q000276:immunology / Q000378:metabolism*; D019496:Cancer Vaccines / Q000276:immunology*; D002469:Cell Separation; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005699:Galactosylceramides / Q000494:pharmacology; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects; D009000:Monocytes / Q000166:cytology; D055611:Natural Killer T-Cells / Q000187:drug effects / Q000276:immunology* / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D055610:Antigens, CD1d; D019496:Cancer Vaccines; D005699:Galactosylceramides; C493154:alpha-galactosylceramide